Mburu MW, Safari MS, Makori TO, Gicheru ET, Nyawa OK, Kuria TC, Foley DJ, Sande CJ
Sci Rep. 2025;15
Cytomegalovirus (CMV) causes infections that last a lifetime and are primarily contracted in childhood. Congenital transmitted CMV is associated with severe neurological sequelae and can cause life-threatening disease in immunocompromised individuals. Although antibodies are generally presumed to correlate with protection, their long-term dynamics remain poorly understood. We aimed to determine the longevity of CMV-specific antibodies in a low-income setting in Kilifi County, Kenya. To track long-term antibody dynamics, we conducted longitudinal surveillance of annually collected serum samples and assayed for antibodies against the CMV tegument phosphoprotein (pp150). The duration of effective immunity against re-infection was estimated using piecewise regression modelling. Serum antibody to CMV was measured in 123 children recruited within the first five years of life and sampled annually over a median of 10 years (range: 7-14). Antibodies to the CMV pp150 showed a cyclic trend of acquisition and loss at the population level. Individually, we observed early antibody acquisition, followed by decline and rebound. Regression analysis identified a 7.57-year inflection point in antibody trajectories, marking a transition from waning to re-accumulation - potentially reflecting natural boosting events in a population where CMV infection occurs early in life. The data show a clear pattern of early natural infection, followed by repeated patterns of antibody acquisition, loss, and re-acquisition over the first decade and a half of life.
